November 2, 2026

@michaelokun

What resonates most with me about this fascinating new study in JAMA Psychiatry is the possibility that psilocybin may do more than improve mood in Parkinson’s disease; it may also influence biological pathways involved in neurodegeneration. In this small, nonrandomized pilot study, 12 individuals with Parkinson’s and mood dysfunction received two doses of psilocybin, and blood samples from nine participants revealed intriguing changes in markers of inflammation and mitochondrial stress. The researchers observed significant reductions in a composite inflammatory index that persisted 30 days after treatment, along with short-term reductions in GDF-15, a marker associated with mitochondrial stress. These findings are especially interesting because inflammation and mitochondrial dysfunction are two important biological processes implicated in Parkinson’s disease. However, we must be cautious. This was a very small study without a placebo group, and changes in blood biomarkers do not establish that psilocybin protects dopamine neurons, slows disease progression, or modifies Parkinson’s pathology. What excites me most is not the psychedelic itself, but the possibility that we may be uncovering new connections between mood, inflammation, mitochondrial health, and neurodegeneration. We need larger randomized trials, longer follow-up, and direct measures of brain biology before drawing conclusions about treatment. The real question is whether we can move beyond treating symptoms and begin targeting the biological processes driving Parkinson’s disease. This study opens an interesting door, but we are still a long way from knowing what lies on the other side. https://cutt.ly/DyUWvMEF